30
Mar
2025
Looking Back and Seeing The Future: The Relationships that Propel Biotech
It’s been a rough week (again) for those of us within the biotech ecosystem. Actually, it’s been a rough month. Hell, let’s just say it’s been a hard year. Or two. Rather than writing about the negatives – there will be plenty of time for that, I suspect – I’d like to share a delightful little story. I recently returned... Read More
22
Dec
2020
Listening Through The Noise and Talking to Those Who Will Listen
Pediatric oncologists like me tend to know their cancer chemotherapy combinations, chapter and verse. But for me and many of my colleagues, vaccines have always loomed large, integral to the “pediatric” part of our medical training. As a medical student in the late 1990s and a resident in pediatrics during the early 2000s, vaccination was a constant source of discussion.... Read More
6
Dec
2017
“You Went to SITC and All You Got Was This TR Post? (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Nov
2017
You Went to SITC And All You Got Was This TR Post? (Part 1)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2017
AACR Reflections: Genomics Adapts to I-O World, Scientists Stand Up, and Re-Thinking How to Fight Early-Stage Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.